Summary

Naltrexone And Buprenorphine Market Summary

The global naltrexone and buprenorphine market size was estimated at USD 4.17 billion in 2024 and is projected to reach USD 9.80 billion by 2033, growing at a CAGR of 9.25% from 2025 to 2033. The market is expected to grow due to the increasing prevalence of substance use disorders and greater awareness of opioid use disorder treatments. Government initiatives are further increasing access to advanced addiction care solutions.

WHO Updates Opioid Treatment Guidelines

In February 2025, The World Health Organization (WHO) updated its guidelines on opioid dependence treatment and overdose prevention to expand access to effective interventions. The revised guidelines emphasized the importance of using opioid agonist maintenance treatment (OAMT) with methadone or buprenorphine as the most effective therapy for opioid dependence. WHO also recommended making naloxone more widely available to prevent overdose-related deaths, especially in community settings. The new guidance called for reducing regulatory barriers and increasing investment in harm-reduction services. Additionally, the update urged healthcare providers to deliver evidence-based, person-centered, and non-discriminatory care. These recommendations were aimed at supporting countries in addressing rising opioid-related health challenges and enhancing public health outcomes globally.

Global Naltrexone And Buprenorphine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global naltrexone and buprenorphine market report based on product, route of administration, application, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Naltrexone
• Buprenorphine
o BELBUCA
o Sublocade
o Suboxone
o Zubsolv
o Others
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Naltrexone
o Oral Administration
o Injectable Administration
o Implantable Administration
• Buprenorphine
o Oral Administration
o Injectable Administration
o Implantable Administration
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Naltrexone
o Opioid use disorder (OUD)
o Alcohol use disorder (AUD
• Buprenorphine
o Opioid use disorder (OUD)
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals Pharmacies
• Retail Pharmacies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Route of Administration
1.2.3. Application
1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Naltrexone and Buprenorphine Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Naltrexone and Buprenorphine Market: Product Business Analysis
4.1. Product Market Share, 2024 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Naltrexone
4.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
4.5. Buprenorphine
4.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
4.5.2. BELBUCA
4.5.2.1. BELBUCA Market, 2021 - 2033 (USD Million)
4.5.3. Sublocade
4.5.3.1. Sublocade Market, 2021 - 2033 (USD Million)
4.5.4. Suboxone
4.5.4.1. Suboxone Market, 2021 - 2033 (USD Million)
4.5.5. Zubsolv
4.5.5.1. Zubsolv Market, 2021 - 2033 (USD Million)
4.5.6. Others
4.5.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. Naltrexone and Buprenorphine Market: Route of Administration Business Analysis
5.1. Route of Administration Market Share, 2024 & 2033
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
5.4. Naltrexone
5.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
5.4.2. Oral Administration
5.4.2.1. Oral Administration Market, 2021 - 2033 (USD Million)
5.4.3. Injectable Administration
5.4.3.1. Injectable Administration Market, 2021 - 2033 (USD Million)
5.4.4. Implantable Administration
5.4.4.1. Implantable Administration Market, 2021 - 2033 (USD Million)
5.5. Buprenorphine
5.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
5.5.2. Oral Administration
5.5.2.1. Oral Administration Market, 2021 - 2033 (USD Million)
5.5.3. Injectable Administration
5.5.3.1. Injectable Administration Market, 2021 - 2033 (USD Million)
5.5.4. Implantable Administration
5.5.4.1. Implantable Administration Market, 2021 - 2033 (USD Million)
Chapter 6. Naltrexone and Buprenorphine Market: Application Business Analysis
6.1. Application Market Share, 2024 & 2033
6.2. Application Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Naltrexone
6.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
6.4.2. Opioid use disorder (OUD)
6.4.2.1. Opioid use disorder (OUD) Market, 2021 - 2033 (USD Million)
6.4.3. Alcohol use disorder (AUD)
6.4.3.1. Alcohol use disorder (AUD) Market, 2021 - 2033 (USD Million)
6.5. Buprenorphine
6.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
6.5.2. Opioid use disorder (OUD)
6.5.2.1. Opioid use disorder (OUD) Market, 2021 - 2033 (USD Million)
Chapter 7. Naltrexone and Buprenorphine Market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2024 & 2033
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
7.5. Retail Pharmacies
7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
7.6. Others
7.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 8. Naltrexone and Buprenorphine Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2033
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
8.4. North America
8.4.1. North America Naltrexone and Buprenorphine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. End Use Disease Prevalence
8.4.2.3. Regulatory Framework
8.4.2.4. Reimbursement Framework
8.4.2.5. U.S. Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. End Use Disease Prevalence
8.4.3.3. Regulatory Framework
8.4.3.4. Reimbursement Framework
8.4.3.5. U.S. Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. End Use Disease Prevalence
8.4.4.3. Regulatory Framework
8.4.4.4. Reimbursement Framework
8.4.4.5. Mexico Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Europe
8.5.1. Europe Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. End Use Disease Prevalence
8.5.2.3. Regulatory Framework
8.5.2.4. Reimbursement Framework
8.5.2.5. Uk Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. End Use Disease Prevalence
8.5.3.3. Regulatory Framework
8.5.3.4. Reimbursement Framework
8.5.3.5. Germany Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. End Use Disease Prevalence
8.5.4.3. Regulatory Framework
8.5.4.4. Reimbursement Framework
8.5.4.5. France Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. End Use Disease Prevalence
8.5.5.3. Regulatory Framework
8.5.5.4. Reimbursement Framework
8.5.5.5. Italy Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. End Use Disease Prevalence
8.5.6.3. Regulatory Framework
8.5.6.4. Reimbursement Framework
8.5.6.5. Spain Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.7. Denmark
8.5.7.1. Key Country Dynamics
8.5.7.2. End Use Disease Prevalence
8.5.7.3. Regulatory Framework
8.5.7.4. Reimbursement Framework
8.5.7.5. Denmark Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.8. Sweden
8.5.8.1. Key Country Dynamics
8.5.8.2. End Use Disease Prevalence
8.5.8.3. Regulatory Framework
8.5.8.4. Reimbursement Framework
8.5.8.5. Sweden Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.9. Norway
8.5.9.1. Key Country Dynamics
8.5.9.2. End Use Disease Prevalence
8.5.9.3. Regulatory Framework
8.5.9.4. Reimbursement Framework
8.5.9.5. Norway Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. End Use Disease Prevalence
8.6.2.3. Regulatory Framework
8.6.2.4. Reimbursement Framework
8.6.2.5. Japan Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. End Use Disease Prevalence
8.6.3.3. Regulatory Framework
8.6.3.4. Reimbursement Framework
8.6.3.5. China Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. End Use Disease Prevalence
8.6.4.3. Regulatory Framework
8.6.4.4. Reimbursement Framework
8.6.4.5. India Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.5. Australia
8.6.5.1. Key Country Dynamics
8.6.5.2. End Use Disease Prevalence
8.6.5.3. Regulatory Framework
8.6.5.4. Reimbursement Framework
8.6.5.5. Australia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.6. South Korea
8.6.6.1. Key Country Dynamics
8.6.6.2. End Use Disease Prevalence
8.6.6.3. Regulatory Framework
8.6.6.4. Reimbursement Framework
8.6.6.5. South Korea Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. End Use Disease Prevalence
8.6.7.3. Regulatory Framework
8.6.7.4. Reimbursement Framework
8.6.7.5. Thailand Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Latin America
8.7.1. Latin America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. End Use Disease Prevalence
8.7.2.3. Regulatory Framework
8.7.2.4. Reimbursement Framework
8.7.2.5. Japan Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. End Use Disease Prevalence
8.7.3.3. Regulatory Framework
8.7.3.4. Reimbursement Framework
8.7.3.5. China Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Middle East and Africa
8.8.1. Middle East and Africa Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. End Use Disease Prevalence
8.8.2.3. Regulatory Framework
8.8.2.4. Reimbursement Framework
8.8.2.5. South Africa Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. End Use Disease Prevalence
8.8.3.3. Regulatory Framework
8.8.3.4. Reimbursement Framework
8.8.3.5. Saudi Arabia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. End Use Disease Prevalence
8.8.4.3. Regulatory Framework
8.8.4.4. Reimbursement Framework
8.8.4.5. UAE Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. End Use Disease Prevalence
8.8.5.3. Regulatory Framework
8.8.5.4. Reimbursement Framework
8.8.5.5. Kuwait Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Indivior PLC
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Collegium Pharmaceutical (BioDelivery Sciences International, Inc.)
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Alkermes, Inc.
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Orexo US, Inc. (a part of Orexo AB)
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Titan Pharmaceuticals, Inc.
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. Omeros Corporation
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Camurus
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Sun Pharmaceutical Industries Ltd
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives